In 1923, Dr. Elliot C. Cutler conducted the world’s first successful mitral valvuloplasty at the Brigham (then Peter Bent Brigham Hospital). On October 20, 2023, the Brigham will mark this important milestone with an all-day CME event looking at past, present, and future approaches to managing mitral valve disease.

Brigham and Women’s Hospital researchers found moderate eGFR decline when transitioning from a renin–angiotensin system inhibitor (RASi) to SV was not consistently associated with adverse outcomes. In addition, long-term benefits of SV were retained in patients with HF across a broad range of initial eGFR declines.

A recent study co-led by Guo-Ping Shi, ScD, and Zhaojie Meng, PhD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, is the first to identify a receptor for eosinophil cationic protein and define its pathogenic role in atherosclerosis.

Researchers used an approach to generate oxidative stress in the vascular endothelium, planning to explore diseases such as hypertension and aortic aneurysms. Surprisingly, the transgenic mice developed neurodegeneration, mitochondrial dysfunction, and cardiac hypertrophy caused by neurovascular oxidative stress.

A collaborative analysis of 31,245 participants in three recent randomized trials suggests residual inflammatory risk is more strongly associated with future cardiovascular events than residual cholesterol risk.

A multicenter quality improvement study, IMPLEMENT-HF, shows that a centralized virtual team make suggestions to treating clinicians about caring for hospitalized patients with HFrEF improved the use of guideline-concordant medical therapy.